Population-based BRCA testing could prevent substantial amount of new cancer cases
BRCA testing based off of clinical criteria and family history often misses a large number of BRCA carriers who would benefit from screening. Researchers in this study estimated that test the general population of women ≥30 years could prevent an additional 2319 to 2666 breast cancer and 327 to 449 ovarian cancers cases per million women than the current clinical strategy’s.
In addition, population-based testing was found to be cost effective in high-income and upper–middle income countries as well as cost effective for high-income countries health systems from a societal perspective.
Read the full study here.
Manchanda R, Sun L, Patel S, et al. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems. Cancers. 2020;12(7):1929; https://doi.org/10.3390/cancers12071929.